Get the Stockscreener App
1.55
6.63%
-0.11
After Hours:
1.55
Connect Biopharma Holdings Ltd stock is traded at $1.55, with a volume of 148.41K.
It is down -6.63% in the last 24 hours and down -12.92% over the past month.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
See More
Previous Close:
$1.66
Open:
$1.645
24h Volume:
148.41K
Relative Volume:
1.37
Market Cap:
$92.51M
Revenue:
-
Net Income/Loss:
$-21.38M
P/E Ratio:
-3.9744
EPS:
-0.39
Net Cash Flow:
$-25.19M
1W Performance:
-9.36%
1M Performance:
-12.92%
6M Performance:
+93.75%
1Y Performance:
+37.17%
1-Day Range:
$1.53
$1.6699
1-Week Range:
$1.53
$1.74
52-Week Range:
$0.51
$2.86
Connect Biopharma Holdings Ltd Stock (CNTB) Company Profile
Name
Connect Biopharma Holdings Ltd
Sector
Industry
Phone
858-727-1040
Address
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
Compare CNTB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd
|
1.55 | 92.51M | 0 | -21.38M | -25.19M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Connect Biopharma Holdings Ltd Stock (CNTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Initiated | BTIG Research | Buy |
| Jun-12-25 | Initiated | H.C. Wainwright | Buy |
| Mar-04-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Apr-13-21 | Initiated | Piper Sandler | Overweight |
| Apr-13-21 | Initiated | SVB Leerink | Outperform |
View All
Connect Biopharma Holdings Ltd Stock (CNTB) Latest News
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 - Bucyrus Telegraph-Forum
This Immuneering Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Connect Biopharma stock initiated with Buy rating at BTIG on respiratory drug potential - Investing.com Nigeria
BTIG Initiates Coverage on Connect Biopharma Hldgs (CNTB) with 'Buy' Rating | CNTB Stock News - GuruFocus
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Short Interest Update - MarketBeat
Connect Biopharma (NASDAQ:CNTB) Stock Price Down 3.8%What's Next? - MarketBeat
All In Solutions Detox Enhances California Center Recovery Environment Through Tranquil Setting - The News Journal
RestoPros of Southwest Florida Expands Damage Restoration Services Across Multiple Counties - azcentral.com and The Arizona Republic
Connect Biopharma's (CNTB) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Hyperke Growth Partners Reveals How They Help SEO Agencies with Qualified Lead Generation in Case Study - azcentral.com and The Arizona Republic
Connect Biopharma's (CNTB) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Severe Asthma Pipeline 2025: Therapies Under Investigation, - openPR.com
Connect Biopharma (NASDAQ:CNTB) Stock Price Up 7.4%Still a Buy? - MarketBeat
Connect Biopharma Holdings Limited (CNTB) stock price, news, quote and history - Yahoo
October 2025's Promising Penny Stocks To Consider - Yahoo Finance
Short Interest in Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Drops By 53.6% - MarketBeat
H.C. Wainwright reiterates Buy rating on Connect Biopharma stock at $7 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on Connect Biopharma stock at $7 target - Investing.com Nigeria
507mL Lung Function Improvement: Connect Bio's New Asthma Drug Shows Remarkable Results in High-Risk Patients - Stock Titan
James Huang to join CASI Pharmaceuticals board as independent director By Investing.com - Investing.com Australia
CASI Pharmaceuticals Appoints James Huang to Board of Directors - ACCESS Newswire
35-Year Biotech Veteran James Huang Joins CASI Pharma Board as Company Advances CID-103 Program - Stock Titan
Eosinophilic Asthma Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharma - Barchart.com
Eosinophilic Asthma Pipeline 2025: Therapies, MOA Insights, - openPR.com
FY2025 EPS Estimate for Connect Biopharma Lowered by Analyst - MarketBeat
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Sees Large Drop in Short Interest - MarketBeat
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Short Interest Up 204.8% in August - MarketBeat
Asthma Market to Show Paltry Growth at a CAGR of 1.95% During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Sees Large Increase in Short Interest - Defense World
Connect Biopharma Announces Poster Presentations of Rademikibart at the European Respiratory Society Congress 2025 - Quiver Quantitative
New Asthma Treatment Data: Connect Biopharma's Rademikibart Shows Impact on FEV1 in Type 2 Asthma Trial - Stock Titan
Connect Biopharma completes termination of its American depositary receipt program and directly lists its ordinary shares on Nasdaq - MarketScreener
Connect Biopharma Ends ADR Program, Moves to Direct Nasdaq Listing; Shares Up Premarket - MarketScreener
Connect Biopharma Completes Termination of its American - GlobeNewswire
Biotech Connect Biopharma Completes Strategic Shift to Direct Nasdaq Listing for U.S. Growth - Stock Titan
COPD Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma - Barchart.com
3 Penny Stocks To Watch With Market Caps Over $100M - simplywall.st
Connect Biopharma (CNTB) Expected to Announce Quarterly Earnings on Friday - Defense World
Connect Biopharma Holdings Limited to Participate in Upcoming Healthcare Conferences - Quiver Quantitative
Connect Biopharma Holdings Ltd Stock (CNTB) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):